PT  - JOURNAL ARTICLE
AU  - Jim M Wild
AU  - Joanna C Porter
AU  - Philip L Molyneaux
AU  - Peter M George
AU  - Iain Stewart
AU  - Richard James Allen
AU  - Raminder Aul
AU  - John Kenneth Baillie
AU  - Shaney L Barratt
AU  - Paul Beirne
AU  - Stephen M Bianchi
AU  - John F Blaikley
AU  - Jonathan Brooke
AU  - Nazia Chaudhuri
AU  - Guilhem Collier
AU  - Emma K Denneny
AU  - Annemarie Docherty
AU  - Laura Fabbri
AU  - Michael A Gibbons
AU  - Fergus V Gleeson
AU  - Bibek Gooptu
AU  - Ian P Hall
AU  - Neil A Hanley
AU  - Melissa Heightman
AU  - Toby E Hillman
AU  - Simon R Johnson
AU  - Mark G Jones
AU  - Fasihul Khan
AU  - Rod Lawson
AU  - Puja Mehta
AU  - Jane A Mitchell
AU  - Manuela Platé
AU  - Krisnah Poinasamy
AU  - Jennifer K Quint
AU  - Pilar Rivera-Ortega
AU  - Malcolm Semple
AU  - A John Simpson
AU  - DJF Smith
AU  - Mark Spears
AU  - LIsa G Spencer
AU  - Stefan C Stanel
AU  - David R Thickett
AU  - A A Roger Thompson
AU  - Simon LF Walsh
AU  - Nicholas D Weatherley
AU  - Mark Everard Weeks
AU  - Dan G Wootton
AU  - Chris E Brightling
AU  - Rachel C Chambers
AU  - Ling-Pei Ho
AU  - Joseph Jacob
AU  - Karen Piper Hanley
AU  - Louise V Wain
AU  - R Gisli Jenkins
TI  - Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
AID  - 10.1136/bmjresp-2021-001049
DP  - 2021 Sep 01
TA  - BMJ Open Respiratory Research
PG  - e001049
VI  - 8
IP  - 1
4099  - http://bmjopenrespres.bmj.com/content/8/1/e001049.short
4100  - http://bmjopenrespres.bmj.com/content/8/1/e001049.full
SO  - BMJ Open Resp Res2021 Sep 01; 8
AB  - Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.